Does SGLT2i use reduce mortality and hospitalizations compared to furosemide and metformin in patients with heart failure and type 2 diabetes mellitus?
Real-world observational data suggests SGLT2 inhibitors are associated with lower mortality and hospitalizations compared to furosemide and metformin in patients with HF and T2DM.
In this real-world analysis, SGLT2i use was associated with lower mortality and fewer hospitalizations compared with furosemide and metformin in patients with HF and T2DM. These findings should be interpreted as associations rather than causal effects due to the observational design and potential residual confounding. The results are hypothesis-generating and directionally consistent with prior randomized evidence.
Daise et al. (Tue,) studied this question.